Abstract: TH-PO644
Therapeutic Effect of Arsenic Trioxide in Human Lupus Nephritis: Results from Network Pharmacology and Ex Vivo Studies
Session Information
- Lupus Nephritis: Clinical, Outcomes, and Therapeutics
October 24, 2024 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Author
- Xie, Ruiyan, The University of Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong, Hong Kong
Background
The renal response to standard treatments of lupus nephritis (LN) often remains suboptimal. Preliminary studies showed efficacy of low-dose arsenic trioxide (ATO) in active systemic lupus erythematosus (SLE), but the mechanisms of action are poorly understood.
Methods
Three machine learning approaches and network pharmacology were applied to screen out the predictive targets of differentially expressed genes (DEGs) from human SLE and LN peripheral blood mononuclear cells (PBMCs) and kidney biopsy datasets. Functional enrichment analysis was conducted. The relationship between characteristic genes and inflammatory cell infiltration was further analyzed and validated in ex-vivo experiments.
Results
Twelve predictive intersected DEGs in SLE patients were selected. Functional enrichment analysis showed a strong association between IL-17 signaling pathway and ATO in SLE (p =1.67E-18). Amongst these DEGs, five immunoregulatory genes were further identified by machine learning models, with MMP9 showing the highest AUC (0.942) by ROC curve analysis. Similar results were validated in kidney biopsy and PBMCs from different LN datasets. Our in vitro experiments showed that ATO could downregulate MMP9 and IL17 expression in PBMCs isolated from LN patients (n=5). Ex-vivo studies suggested that ATO may induce apoptosis and inhibit proliferation of CpG-stimulated CD19+ B cells from LN patients.
Conclusion
ATO shows promising effects on B lymphocyte inhibition via downregulation of MMP9, and hence has good potential to be repurposed for the treatment of SLE and LN.
Fig1
Fig2
Funding
- Other NIH Support